By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Incyte Corporation 

Experimental Station
Route 141 & Henry Clay Road, Building E336
Wilmington  Delaware  19880  U.S.A.
Phone: 302-498-6700 Fax: 302-425-2750


Company News
Incyte (INCY) to Hire 400 as Delaware Officials Mull Possibilities of Attracting More Health Science Companies 11/16/2015 6:36:08 AM
Eli Lilly (LLY) And Incyte (INCY) Announce Patients Treated With Baricitinib Demonstrated Significant Improvement In Signs And Symptoms Of Rheumatoid Arthritis Compared With Methotrexate 11/9/2015 6:32:56 AM
Incyte (INCY) Release: Epacadostat In Combination With Pembrolizumab Demonstrates Promising Clinical Activity In Multiple Advanced Cancers 11/3/2015 11:08:57 AM
Incyte (INCY) Reports 2015 Third-Quarter Financial Results And Updates Shareholders On Key Clinical Programs 11/3/2015 10:42:20 AM
Eli Lilly (LLY) And Incyte (INCY) Announce Webcast To Discuss Baricitinib Phase 3 Data 10/27/2015 11:07:08 AM
Eli Lilly (LLY), Incyte (INCY)'s RA-BEAM Study Met its Primary Objective in Phase III 10/14/2015 9:32:37 AM
Incyte (INCY) And Merck & Co. (MRK) Expand Clinical Collaboration To Include Phase 3 Study Investigating The Combination Of Epacadostat With Keytruda (Pembrolizumab) As First-Line Treatment For Advanced Melanoma 10/13/2015 12:52:34 PM
Incyte (INCY) To Report Third Quarter Financial Results 10/13/2015 11:05:32 AM
Data At SITC Annual Meeting To Highlight Progress Of Incyte (INCY)’s Immuno-oncology Portfolio 10/2/2015 10:08:31 AM
Data At SITC Annual Meeting To Highlight Progress Of Incyte (INCY)’s Immuno-Oncology Portfolio 10/2/2015 7:29:23 AM